Mat Trachok

Senior Associate


Mat Trachok's practice focuses on advising clients on technology-centered transactions. Mr. Trachok's clients are in the high technology, hardware, software, Internet, biotechnology, pharmaceutical, medical device and service industries, and span the range from established to emerging companies. Mr. Trachok advises clients on developing term sheets and negotiating and drafting complex commercial and intellectual property transactions, including licensing, research collaboration, sale, supply, service and Internet use agreements.

From 2012 to 2015, Mr. Trachok litigated intellectual property and breach of contract disputes, at the state and federal trial and appellate levels, involving a broad range of technologies, including pharmaceuticals, medical devices, optical networks, near field communication, network interfaces and crop planters. Mr. Trachok's litigation practice encompassed all stages of litigation—from pre-suit investigations through discovery, summary judgment, trial, settlement, alternative dispute resolution and appeal. His appellate experience included the United States Court of Appeals for the Federal Circuit, the Massachusetts Supreme Judicial Court and the Supreme Court of the State of Vermont.


Prior to joining WilmerHale, Mr. Trachok was a National Security Law teaching assistant at Harvard Law School. In the summer of 2010, Mr. Trachok was an intern for Judge Wallach of the United States Court of International Trade. While there, he aided in adjudicating cases before the court and assisted with advising the American Law Institute on the fourth draft of Legal and Economic Principles of World Trade Law: National Treatment. In 2008, Mr. Trachok was an intern in the Office of Senator Harry Reid, where he worked with Senator Reid's foreign policy advisors.

Publications & News


March 20, 2018

WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration.

May 2, 2017

WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target.

October 4, 2016

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

WilmerHale client Summit Therapeutics plc and Sarepta Therapeutics announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States.


Skip Navigation Links.


HBX | Harvard Business School, Credential of Readiness (CORe), Business Analytics, Financial Accounting, Economics for Managers, with High Honors, 2016

JD, cum laude, Harvard Law School, 2012, Editor-in-Chief, National Security Journal

BA, International Studies and English, cum laude, Yale University, 2009

Bar Admissions


Skip Navigation Links.